High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors
1998

High-dose therapy for germ cell tumors

Sample size: 31 publication Evidence: moderate

Author Information

Author(s): MPA Lyttelton, ES Newlands, C Giles, M Bower, A Guimaraes, S O'Reilly, GJS Rustin, D Samson, EJ Kanfer

Primary Institution: Imperial College School of Medicine, Hammersmith Hospitals NHS Trust, London, UK

Hypothesis

Can high-dose therapy with carboplatin adjusted for renal function improve outcomes in patients with relapsed or refractory germ cell tumors?

Conclusion

The study found that high-dose therapy is effective for a significant number of patients with primary refractory or relapsed germ cell tumors.

Supporting Evidence

  • The 3-year probability of overall survival was 41%.
  • The 3-year probability of disease-free survival was 28%.
  • One patient died due to acute renal failure, representing 3% mortality.

Takeaway

Doctors gave strong medicine to help sick patients with a type of cancer, and many of them got better.

Methodology

Patients received high-dose therapy with autologous stem cell support and carboplatin dosage adjusted based on kidney function.

Limitations

The study was not randomized and had a small sample size.

Participant Demographics

All 31 patients were male with advanced germ cell tumors.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication